NASDAQ:TSHA Taysha Gene Therapies (TSHA) Stock Price, News & Analysis $2.72 -0.09 (-3.20%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$2.75 +0.03 (+1.25%) As of 08/8/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Taysha Gene Therapies Stock (NASDAQ:TSHA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Taysha Gene Therapies alerts:Sign Up Key Stats Today's Range$2.70▼$2.8550-Day Range$2.31▼$2.8852-Week Range$1.05▼$3.31Volume1.10 million shsAverage Volume2.76 million shsMarket Capitalization$583.88 millionP/E RatioN/ADividend YieldN/APrice Target$8.17Consensus RatingBuy Company Overview Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. Read More Taysha Gene Therapies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreTSHA MarketRank™: Taysha Gene Therapies scored higher than 59% of companies evaluated by MarketBeat, and ranked 403rd out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingTaysha Gene Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTaysha Gene Therapies has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Taysha Gene Therapies' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Taysha Gene Therapies are expected to decrease in the coming year, from ($0.35) to ($0.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Taysha Gene Therapies is -8.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Taysha Gene Therapies is -8.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTaysha Gene Therapies has a P/B Ratio of 7.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Taysha Gene Therapies' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.48% of the outstanding shares of Taysha Gene Therapies have been sold short.Short Interest Ratio / Days to CoverTaysha Gene Therapies has a short interest ratio ("days to cover") of 11.4, which indicates bearish sentiment.Change versus previous monthShort interest in Taysha Gene Therapies has recently increased by 2,952.78%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTaysha Gene Therapies does not currently pay a dividend.Dividend GrowthTaysha Gene Therapies does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted20.48% of the outstanding shares of Taysha Gene Therapies have been sold short.Short Interest Ratio / Days to CoverTaysha Gene Therapies has a short interest ratio ("days to cover") of 11.4, which indicates bearish sentiment.Change versus previous monthShort interest in Taysha Gene Therapies has recently increased by 2,952.78%, indicating that investor sentiment is decreasing significantly. News and Social Media3.0 / 5News Sentiment0.42 News SentimentTaysha Gene Therapies has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Taysha Gene Therapies this week, compared to 3 articles on an average week.Search Interest18 people have searched for TSHA on MarketBeat in the last 30 days. This is an increase of 157% compared to the previous 30 days.MarketBeat Follows13 people have added Taysha Gene Therapies to their MarketBeat watchlist in the last 30 days. This is an increase of 333% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Taysha Gene Therapies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,062,500.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.78% of the stock of Taysha Gene Therapies is held by insiders.Percentage Held by Institutions77.70% of the stock of Taysha Gene Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Taysha Gene Therapies' insider trading history. Receive TSHA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Taysha Gene Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address TSHA Stock News HeadlinesTaysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12August 5, 2025 | globenewswire.comWells Fargo Remains Bullish on Taysha Gene Therapies (TSHA)August 5, 2025 | msn.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime. | Brownstone Research (Ad)Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Sees Large Increase in Short InterestAugust 2, 2025 | americanbankingnews.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)August 1, 2025 | globenewswire.comNeedham Maintains a Buy on Taysha Gene Therapies (TSHA), Keeps PT at $8August 1, 2025 | msn.comB of A Securities Initiates Coverage of Taysha Gene Therapies (TSHA) with Buy RecommendationJuly 12, 2025 | msn.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 3, 2025 | globenewswire.comSee More Headlines TSHA Stock Analysis - Frequently Asked Questions How have TSHA shares performed this year? Taysha Gene Therapies' stock was trading at $1.73 on January 1st, 2025. Since then, TSHA stock has increased by 57.2% and is now trading at $2.72. How were Taysha Gene Therapies' earnings last quarter? Taysha Gene Therapies, Inc. (NASDAQ:TSHA) announced its quarterly earnings data on Thursday, May, 15th. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). The business had revenue of $2.30 million for the quarter, compared to analyst estimates of $1.48 million. Taysha Gene Therapies had a negative trailing twelve-month return on equity of 104.93% and a negative net margin of 1,201.08%. Read the conference call transcript. When did Taysha Gene Therapies IPO? Taysha Gene Therapies (TSHA) raised $125 million in an IPO on Thursday, September 24th 2020. The company issued 6,600,000 shares at $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies served as the underwriters for the IPO and Chardan was co-manager. Who are Taysha Gene Therapies' major shareholders? Top institutional shareholders of Taysha Gene Therapies include Tybourne Capital Management HK Ltd. (1.91%), Geode Capital Management LLC (1.77%), SG Americas Securities LLC (0.23%) and Chicago Partners Investment Group LLC (0.08%). Insiders that own company stock include RA Session II, Paul B Manning, Sean P Nolan, Kamran Alam and Sukumar Nagendran. View institutional ownership trends. How do I buy shares of Taysha Gene Therapies? Shares of TSHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Taysha Gene Therapies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Taysha Gene Therapies investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Alphabet (GOOG), Visa (V) and Walt Disney (DIS). Company Calendar Last Earnings5/15/2025Today8/08/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - GENERIC DRG Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TSHA CIK1806310 Webwww.tayshagtx.com Phone214-612-0000FaxN/AEmployees180Year Founded2020Price Target and Rating Average Price Target for Taysha Gene Therapies$8.17 High Price Target$11.00 Low Price Target$6.00 Potential Upside/Downside+200.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$89.30 million Net Margins-1,201.08% Pretax Margin-1,201.08% Return on Equity-104.93% Return on Assets-50.09% Debt Debt-to-Equity Ratio0.77 Current Ratio5.35 Quick Ratio5.35 Sales & Book Value Annual Sales$8.33 million Price / Sales70.09 Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book7.77Miscellaneous Outstanding Shares214,660,000Free Float206,548,000Market Cap$583.88 million OptionableOptionable Beta0.98 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:TSHA) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Taysha Gene Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Taysha Gene Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.